New advances in microsphere-based single-dose vaccines.

Polymer microspheres have shown great potential as a next generation adjuvant to replace or complement existing aluminum salts for vaccine potentiation. Microsphere-based systems can now be made to deliver subunit protein and peptide antigens in their native form in a continuous or pulsatile fashion for periods of weeks to months with reliable and reproducible kinetics, often obviating the need for booster immunizations in animal models. Microspheres have also shown potential as carriers for oral vaccine delivery due to their protective effects on encapsulated antigens and their ability to be taken up by the Peyer's patches in the intestine. The potency of these optimal depot formulations for antigen may be enhanced by the co-delivery of vaccine adjuvants, including cytokines, that are either entrapped in the polymer matrix or, alternatively, incorporated into the backbone of the polymer itself and released concomitantly with antigen as the polymer degrades. In this article we review the use of polymer microspheres for single-step immunization and discuss future applications for the improvement of vaccines and immunotherapies by utilizing encapsulation technology.

[1]  Michael J. Pikal,et al.  Freeze‐Drying of Proteins. Process, Formulation, and Stability. , 1995 .

[2]  F. Vogel,et al.  A compendium of vaccine adjuvants and excipients. , 1995, Pharmaceutical biotechnology.

[3]  D. Ruble,et al.  Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres , 1995, Infection and immunity.

[4]  R. N. Brogden,et al.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. , 1994, Drugs.

[5]  S. Wharton,et al.  Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system. , 1993, Vaccine.

[6]  K. Mills,et al.  Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. , 1995, Vaccine.

[7]  Rajesh K. Gupta,et al.  Adjuvants--a balance between toxicity and adjuvanticity. , 1993, Vaccine.

[8]  J. Hunt,et al.  Radiation damage to crystalline ribonuclease: identification of polypeptide chain breakage in the denatured and aggregated products. , 1967, Radiation research.

[9]  A. Gettie,et al.  Protection against vaginal SIV transmission with microencapsulated vaccine. , 1993, Science.

[10]  R. Langer,et al.  Controlled release of polypeptides from polyanhydrides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. G. Pitt,et al.  Poly (glycolic acid-co-dl-lactic acid): diffusion or degradation controlled drug delivery? , 1992 .

[12]  J. Eldridge,et al.  Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. , 1989, Advances in experimental medicine and biology.

[13]  M. Helliwell The use of bioadhesives in targeted delivery within the gastrointestinal tract , 1993 .

[14]  R. Langer,et al.  Synthesis and Characterization of Degradable Anhydride-co-imide Terpolymers Containing Trimellitylimido-l-tyrosine: Novel Polymers for Drug Delivery , 1996 .

[15]  D. Rahman,et al.  Biodegradable microparticles for oral immunization. , 1993, Vaccine.

[16]  P. Felgner,et al.  Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[17]  H. Sah,et al.  Continuous release of proteins from biodegradable microcapsules and in vivo evaluation of their potential as a vaccine adjuvant , 1995 .

[18]  J. Cantey,et al.  Specific adherence of Escherichia coli (strain RDEC-1) to membranous (M) cells of the Peyer's patch in Escherichia coli diarrhea in the rabbit. , 1983, The Journal of clinical investigation.

[19]  J. Hunt,et al.  Radiation damage to crystalline ribonuclease: importance of free radicals in the formation of denatured and aggregated products. , 1967, Radiation research.

[20]  J L Cleland,et al.  Development of a single-shot subunit vaccine for HIV-1. 2. Defining optimal autoboost characteristics to maximize the humoral immune response. , 1996, Journal of pharmaceutical sciences.

[21]  E. Gilboa,et al.  Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity , 1990, The Journal of experimental medicine.

[22]  T. Kissel,et al.  INJECTABLE BIODEGRADABLE MICROSPHERES FOR VACCINE DELIVERY , 1996 .

[23]  M. Powell,et al.  Immunological and formulation design considerations for subunit vaccines. , 1995, Pharmaceutical biotechnology.

[24]  W. Cray,et al.  M cell transport of Vibrio cholerae from the intestinal lumen into Peyer's patches: a mechanism for antigen sampling and for microbial transepithelial migration. , 1986, The Journal of infectious diseases.

[25]  K. Rock,et al.  Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. , 1996, Journal of immunology.

[26]  R. Finberg,et al.  Determinants of reovirus interaction with the intestinal M cells and absorptive cells of murine intestine. , 1983, Gastroenterology.

[27]  D. Pardoll Paracrine cytokine adjuvants in cancer immunotherapy. , 1995, Annual review of immunology.

[28]  B. Gander,et al.  A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. , 1995, Vaccine.

[29]  O. Böstman,et al.  Absorbable pins of self-reinforced poly-L-lactic acid for fixation of fractures and osteotomies. , 1992, The Journal of bone and joint surgery. British volume.

[30]  D. Crommelin,et al.  Controlled release of bioactive agents from lactide/glycolide polymers , 1990 .

[31]  H. Sah,et al.  Degradability and antigen‐release characteristics of polyester microspheres prepared from polymer blends , 1995 .

[32]  R. Langer,et al.  Biodegradable polymers as drug delivery systems , 1990 .

[33]  R. Langer,et al.  Drug release from a new family of biodegradable polyanhydrides , 1994 .

[34]  R. Langer,et al.  The pharmacokinetics of, and humoral responses to, antigen delivered by microencapsulated liposomes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Vogelstein,et al.  Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response , 1990, Cell.

[36]  S. Kohbata,et al.  Cytopathogenic Effect of Salmonella typhi GIFU 10007 on M cells of Murine Ileal Peyer's Patches in Ligated Ileal Loops: An Ultrastructural Study , 1986, Microbiology and immunology.

[37]  R. Rappuoli,et al.  Absence of protective immunity against diphtheria in a large proportion of young adults. , 1993, Vaccine.

[38]  R. Langer,et al.  Controlled protein delivery from biodegradable tyrosine-containing poly(anhydride-co-imide) microspheres. , 1997, Biomaterials.

[39]  S. H. Leung,et al.  Binding of acrylic polymers to mucin/epithelial surfaces: structure-property relationships. , 1988, Critical reviews in therapeutic drug carrier systems.

[40]  G. Winde,et al.  Clinical and functional results of abdominal rectopexy with absorbable mesh-graft for treatment of complete rectal prolapse. , 1993, The European journal of surgery = Acta chirurgica.

[41]  R. H. Bruce,et al.  Low vaccination levels of US preschool and school-age children. Retrospective assessments of vaccination coverage, 1991-1992. , 1994, JAMA.

[42]  E. Jaffee,et al.  Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. , 1993, Cancer research.

[43]  A. Klibanov,et al.  Stability of Proteins and Their Delivery from Biodegradable Polymer Microspheres , 1996 .

[44]  M. Powell,et al.  Vaccine Design , 1995, Pharmaceutical Biotechnology.

[45]  R Langer,et al.  Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. , 1985, Journal of biomedical materials research.

[46]  T. Wrin,et al.  Development of a single-shot subunit vaccine for HIV-1. 3. Effect of adjuvant and immunization schedule on the duration of the humoral immune response to recombinant MN gp120. , 1996, Journal of pharmaceutical sciences.

[47]  M. Buggy,et al.  Irradiation of poly-D,L-lactide , 1992 .

[48]  T. Arakawa,et al.  Interactions of Stabilizers with Proteins During Freezing and Drying. , 1995 .

[49]  G. Gregoriadis Immunological adjuvants: a role for liposomes. , 1990, Immunology today.

[50]  R. Gupta,et al.  Stabilization of tetanus and diphtheria toxoids against moisture-induced aggregation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. O'hagan,et al.  Intestinal translocation of particulates — implications for drug and antigen delivery , 1990 .

[52]  J L Cleland,et al.  Protein delivery from biodegradable microspheres. , 1997, Pharmaceutical biotechnology.

[53]  W. Koff,et al.  Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. , 1997, Vaccine.

[54]  A. Shahzamani,et al.  In vivo characterization of sustained-release formulations of human growth hormone. , 1997, The Journal of pharmacology and experimental therapeutics.

[55]  D. O’hagan Novel Delivery Systems for Oral Vaccines , 1994 .

[56]  R. Martuza,et al.  Treatment of glioma by engineered interleukin 4-secreting cells. , 1993, Cancer research.

[57]  R. Langer,et al.  Poly(anhydride) administration in high doses in vivo: studies of biocompatibility and toxicology. , 1990, Journal of biomedical materials research.

[58]  J. Kraehenbuhl,et al.  Transepithelial transport and mucosal defence I: the role of M cells. , 1992, Trends in cell biology.

[59]  J. Cleland Design and production of single-immunization vaccines using polylactide polyglycolide microsphere systems. , 1995, Pharmaceutical biotechnology.

[60]  E. Jaffee,et al.  Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[61]  J. Freund The effect of paraffin oil and mycobacteria on antibody formation and sensitization; a review. , 1951, American journal of clinical pathology.

[62]  A. Shahzamani,et al.  A month–long effect from a single injection of microencapsulated human growth hormone , 1996, Nature Medicine.

[63]  J. Mcghee,et al.  Biodegradable microspheres as a vaccine delivery system. , 1991, Molecular immunology.

[64]  J C Murphy,et al.  Single-step immunization using a controlled release, biodegradable polymer with sustained adjuvant activity. , 1986, Journal of immunological methods.

[65]  R. Langer,et al.  Degradation of porous poly(anhydride-co-imide) microspheres and implications for controlled macromolecule delivery. , 1998, Biomaterials.

[66]  P. Lambert,et al.  Controlled-release vaccines--biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles. , 1992, Immunobiology.

[67]  D. Keren,et al.  Role of M cells in initial antigen uptake and in ulcer formation in the rabbit intestinal loop model of shigellosis , 1989, Infection and immunity.

[68]  J. Benoit,et al.  In vitro and in vivo degradation of poly(D,L lactide/glycolide) type microspheres made by solvent evaporation method. , 1989, Biomaterials.

[69]  K. Rock,et al.  Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Michael Wolff,et al.  The influence of terminal gamma-sterilization on captopril containing poly(d,l-lactide-co-glycolide) microspheres , 1994 .

[71]  C. Kensil,et al.  Structural and immunological characterization of the vaccine adjuvant QS-21. , 1995, Pharmaceutical biotechnology.

[72]  R. Langer,et al.  Formulation and Delivery of Proteins and Peptides. Design and Development Strategies. , 1995 .

[73]  I. Horáček,et al.  Influence of molecular weight on the resistance of polylactide fibers by radiation sterilization , 1993 .

[74]  J L Cleland,et al.  The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. , 1993, Critical reviews in therapeutic drug carrier systems.

[75]  R. Daum,et al.  Accuracy of immunization histories provided by adults accompanying preschool children to a pediatric emergency department. , 1993, JAMA.

[76]  K. Rock,et al.  Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity , 1995, Nature Medicine.

[77]  R K Gupta,et al.  Pulsed controlled-released system for potential use in vaccine delivery. , 1996, Journal of pharmaceutical sciences.

[78]  T. Kissel,et al.  Parameters affecting the immunogenicity of microencapsulated tetanus toxoid. , 1992, Vaccine.

[79]  J L Cleland,et al.  Development of a single-shot subunit vaccine for HIV-1. , 1997, AIDS research and human retroviruses.

[80]  N Lotan,et al.  Large porous particles for pulmonary drug delivery. , 1997, Science.

[81]  C. Alving Delivery of liposome-encapsulated drugs to macrophages. , 1983, Pharmacology & therapeutics.

[82]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[83]  B. Bloom Vaccines for the Third World , 1989, Nature.

[84]  R. Gupta,et al.  Stabilization of tetanus toxoid in poly(DL-lactic-co-glycolic acid) microspheres for the controlled release of antigen. , 1996, Journal of pharmaceutical sciences.

[85]  S. Arya Human immunization in developing countries: practical and theoretical problems and prospects. , 1994, Vaccine.

[86]  Thomas R. Tice,et al.  Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches , 1990 .

[87]  S. Rosenberg,et al.  Immunotherapy and gene therapy of cancer. , 1991, Advances in surgery.

[88]  R. Langer,et al.  A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. , 1997, Journal of pharmaceutical sciences.

[89]  J. Tamada,et al.  The development of polyanhydrides for drug delivery applications. , 1992, Journal of biomaterials science. Polymer edition.

[90]  R. Gupta,et al.  Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. , 1994, Vaccine.

[91]  G. Ada Strategies for exploiting the immune system in the design of vaccines. , 1991, Molecular immunology.

[92]  D. Rahman,et al.  Biodegradable microparticles as controlled release antigen delivery systems. , 1991, Immunology.

[93]  M. Aguado Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems. , 1993, Vaccine.

[94]  Brooks M. Boyd,et al.  Recombinant human growth hormone poly(lactic-co-glycolic acid) (PLGA) microspheres provide a long lasting effect , 1997 .

[95]  G. Stollerman,et al.  The measles epidemic. The problems, barriers, and recommendations. The National Vaccine Advisory Committee. , 1991, JAMA.

[96]  Noah Lotan,et al.  Large porous aerosols for pulmonary drug delivery , 1997 .

[97]  V. Stevens,et al.  Vaccine Delivery Systems: Potential Methods for Use in Antifertility Vaccines , 1993, American journal of reproductive immunology.

[98]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[99]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[100]  Y. Ikada,et al.  Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers. , 1988, Journal of biomedical materials research.

[101]  P. Leder,et al.  Murine interleukin-4 displays potent anti-tumor activity in vivo , 1989, Cell.

[102]  Robert Langer,et al.  Polymerization Reactions Involving the Side Chains of α-L-Amino Acids , 1987 .

[103]  R. Langer,et al.  Polymer microspheres for vaccine delivery. , 1995, Pharmaceutical biotechnology.

[104]  R. Zhuo,et al.  Synthesis and Biological Properties of Polymer Immunoadjuvants , 1993 .

[105]  X M Li,et al.  Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. , 1996, Vaccine.

[106]  J. Fox,et al.  Evaluation of ethylene-vinyl acetate copolymer as a non-inflammatory alternative to Freund's complete adjuvant in rabbits. , 1985, Laboratory animal science.

[107]  W. Wooden,et al.  Subcuticular sutures and the rate of inflammation in noncontaminated wounds. , 1995, Annals of emergency medicine.

[108]  R. Langer,et al.  A single-step immunization by sustained antigen release. , 1979, Journal of immunological methods.

[109]  N. Jacobsen,et al.  Isomerization and formulation stability of the vaccine adjuvant QS-21. , 1996, Journal of pharmaceutical sciences.

[110]  J. Warchoł,et al.  Poliovirus type 1 enters the human host through intestinal M cells. , 1990, Gastroenterology.